ATE399554T1 - Pharmazeutische zusammensetzung enthaltend tadalafil - Google Patents

Pharmazeutische zusammensetzung enthaltend tadalafil

Info

Publication number
ATE399554T1
ATE399554T1 AT00926371T AT00926371T ATE399554T1 AT E399554 T1 ATE399554 T1 AT E399554T1 AT 00926371 T AT00926371 T AT 00926371T AT 00926371 T AT00926371 T AT 00926371T AT E399554 T1 ATE399554 T1 AT E399554T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
composition containing
containing tadalafil
tadalafil
disintegrant
Prior art date
Application number
AT00926371T
Other languages
English (en)
Inventor
Neil Anderson
Rampurna Gullapalli
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22519593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE399554(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Application granted granted Critical
Publication of ATE399554T1 publication Critical patent/ATE399554T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00926371T 1999-08-03 2000-04-26 Pharmazeutische zusammensetzung enthaltend tadalafil ATE399554T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14692499P 1999-08-03 1999-08-03

Publications (1)

Publication Number Publication Date
ATE399554T1 true ATE399554T1 (de) 2008-07-15

Family

ID=22519593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00926371T ATE399554T1 (de) 1999-08-03 2000-04-26 Pharmazeutische zusammensetzung enthaltend tadalafil

Country Status (29)

Country Link
US (2) US7182958B1 (de)
EP (3) EP1200091B1 (de)
JP (2) JP2003505509A (de)
KR (2) KR100738861B1 (de)
CN (1) CN1213754C (de)
AT (1) ATE399554T1 (de)
AU (2) AU776722B2 (de)
BR (1) BR0012863A (de)
CA (1) CA2379948C (de)
CZ (1) CZ304624B6 (de)
DE (1) DE60039357D1 (de)
DK (1) DK1200090T3 (de)
DZ (1) DZ3179A1 (de)
EA (1) EA004872B1 (de)
ES (2) ES2435816T3 (de)
HK (1) HK1044277B (de)
HR (1) HRP20020090B1 (de)
HU (1) HU230660B1 (de)
IL (2) IL147641A0 (de)
MX (1) MXPA02001196A (de)
NO (1) NO321649B1 (de)
NZ (1) NZ516616A (de)
PL (1) PL199137B1 (de)
PT (1) PT1200090E (de)
SI (1) SI1200090T1 (de)
SK (1) SK287869B6 (de)
UA (1) UA72922C2 (de)
WO (2) WO2001008686A1 (de)
ZA (1) ZA200200823B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
ATE399554T1 (de) * 1999-08-03 2008-07-15 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
MXPA03009750A (es) 2001-04-25 2004-06-30 Lilly Icos Llc Compuestos quimicos.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (de) 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
EP1321142A1 (de) * 2001-12-21 2003-06-25 Novartis AG Feste orale Zubereitung mit Tegaserod
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
KR20080083071A (ko) 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
EP1923053A1 (de) 2006-09-27 2008-05-21 Novartis AG Pharmazeutische Zusammensetzung umfassend Nilotinib oder dessen Salz
ES2405787T3 (es) 2007-04-25 2013-06-03 Teva Pharmaceutical Industries Ltd. Formas de dosificación solidas
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
EP2042165A1 (de) * 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Hot-Melt-Befüllte Weichkapseln
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2010099323A1 (en) 2009-02-26 2010-09-02 Thar Pharmaceuticals, Inc. Crystalization of pharmaceutical compounds
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009035211A1 (de) 2009-07-29 2011-02-17 Ratiopharm Gmbh Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
EP2517705B1 (de) 2009-12-21 2016-10-19 Acef S/A Cubebin als vasodilatator bei der behandlung von erektiler dysfunktion
WO2012095151A1 (en) 2010-12-23 2012-07-19 Zaklady Farmaceutyczne Polpharma Sa Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
EP2535049A1 (de) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil zur Behandlung von Demenz
WO2014027979A2 (en) 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet formulations comprising tadalafil and dapoxetine
US20150320677A1 (en) 2012-08-17 2015-11-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
WO2014027975A2 (en) 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel orally administered pharmaceutical formulations
WO2014027982A2 (en) 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
WO2014125343A1 (en) * 2013-02-12 2014-08-21 Alembic Pharmaceuticals Limited Tadalafil tablet composition with reduced dose strength
BR112015025859A2 (pt) 2013-04-11 2017-07-25 Ctc Bio Inc forma de dosagem de filme contendo base livre de tadalafila contendo polímero à base de polietilenoglicol e/ou polímero à base de vinilpirrolidona como estabilizador de dispersão
US20160129017A1 (en) 2013-07-01 2016-05-12 The Research Foundation for the State University New York Ship inhibition to combat obesity
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
WO2015195812A1 (en) 2014-06-17 2015-12-23 The Research Foundation For The State University Of New York Ship inhibition to induce activation of natural killer cells
EP2962684A1 (de) 2014-06-30 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Im mund zerfallende formulierungen von tadalafil
WO2016001143A1 (en) 2014-06-30 2016-01-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Orally disintegrating formulations of tadalafil
KR101648051B1 (ko) 2014-09-01 2016-08-12 주식회사 인트로팜텍 타다라필을 포함하는 휴대용 구강붕해정, 및 이의 제조방법
KR101538985B1 (ko) 2014-09-02 2015-07-24 주식회사 서울제약 타다라필 구강붕해필름 및 이의 제조방법
CN104758941A (zh) * 2015-04-27 2015-07-08 浙江永宁药业股份有限公司 一种利用羟丙基纤维素为粘合剂实现快速溶出的口服片剂
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514758D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
WO2017104862A1 (ko) * 2015-12-16 2017-06-22 동국제약 주식회사 타달라필 및 두타스테라이드를 포함하는 복합제제 조성물 및 그 제조방법
KR101716878B1 (ko) * 2016-05-12 2017-03-15 주식회사 유유제약 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
EP3554507A1 (de) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von pulmonaler hypertonie und anderen lungenerkrankungen
IT201700015145A1 (it) * 2017-02-10 2018-08-10 Altergon Sa Capsule di gelatina molle ad elevata stabilità
CN106821991A (zh) * 2017-03-21 2017-06-13 南京正科医药股份有限公司 一种微粒径他达拉非的制备方法
JP2019065006A (ja) 2017-09-29 2019-04-25 ハンミ ファーマシューティカルズ カンパニー リミテッド 生産性及び均一性が改善されたタダラフィルを含む固形製剤、及びその製造方法
JP2021509114A (ja) 2017-12-26 2021-03-18 エフティーエフ ファーマ プライベート リミテッド Ｐｄｅ ｖ阻害剤のための液体経口処方物
EP3510997B1 (de) 2018-01-10 2020-08-05 Gap S.A. Weichgelatinekapseln mit einer suspension für tadalafil
US20210137919A1 (en) * 2018-02-07 2021-05-13 Smawa Gmbh Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer
CN110638770B (zh) * 2019-10-25 2022-04-05 株洲千金药业股份有限公司 他达拉非片剂的制备方法及以该方法制得的片剂
EP4531815A1 (de) 2022-05-27 2025-04-09 Rontis Hellas S.A. Verbesserte pharmazeutische zusammensetzung mit tadalafil und nanomühlungsverfahren zur herstellung davon

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328929D0 (en) * 1983-10-29 1983-11-30 Sterwin Ag Steroid compounds
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
JPH0347124A (ja) * 1989-04-20 1991-02-28 Fujisawa Pharmaceut Co Ltd 経口吸収用製剤
JPH0818985B2 (ja) * 1989-05-30 1996-02-28 吉富製薬株式会社 溶出性の改良された製剤組成物
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
FR2710153B1 (fr) * 1993-09-17 1995-12-01 Alpha Mos Sa Procédés et appareils de détection des substances odorantes et applications.
DK1033128T4 (da) * 1993-09-28 2012-03-19 Scherer Gmbh R P Blød gelatinekapselfremstilling
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
JP2001504502A (ja) * 1996-11-28 2001-04-03 ノボ ノルディスク アクティー ゼルスカブ 薬学的製剤
JP4292588B2 (ja) * 1997-01-31 2009-07-08 日産化学工業株式会社 ピリダジノン化合物類の経口製剤
HUP0003078A3 (en) * 1997-07-11 2002-02-28 Janssen Pharmaceutica Nv (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
BR9813699A (pt) * 1997-12-16 2000-10-10 Pfizer Prod Inc Combinação eficaz para o tratamento da impotência
JP2000178204A (ja) * 1998-10-05 2000-06-27 Eisai Co Ltd ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
JP2000191518A (ja) * 1998-10-19 2000-07-11 Eisai Co Ltd 溶解性の改善された口腔内速崩壊性錠剤
AU3724400A (en) 1999-03-08 2000-09-28 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
EP1173167A4 (de) * 1999-04-30 2004-07-14 Lilly Icos Llc Behandlung der störungen der weiblichen erregbarkeit
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
SV2002000055A (es) * 1999-04-30 2002-07-03 Lilly Icos Llc Articulos de manufactura ref. n0. 29342/36212 sv
ATE399554T1 (de) * 1999-08-03 2008-07-15 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil
UA71629C2 (en) * 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction

Also Published As

Publication number Publication date
HRP20020090B1 (hr) 2014-03-28
DE60039357D1 (de) 2008-08-14
SK287869B6 (sk) 2012-02-03
EP2338491A2 (de) 2011-06-29
EP2338491A3 (de) 2011-11-30
HU230660B1 (hu) 2017-06-28
EP1200090A1 (de) 2002-05-02
CN1213754C (zh) 2005-08-10
PT1200090E (pt) 2013-11-25
UA72922C2 (uk) 2005-05-16
HRP20020090A2 (en) 2003-12-31
HK1044277B (en) 2014-02-28
PL353304A1 (en) 2003-11-03
AU776722B2 (en) 2004-09-16
EP1200090B1 (de) 2013-09-11
EA200200118A1 (ru) 2002-06-27
JP2010163464A (ja) 2010-07-29
NO321649B1 (no) 2006-06-19
JP2003505509A (ja) 2003-02-12
HUP0202513A2 (en) 2002-10-28
EP1200091A1 (de) 2002-05-02
SI1200090T1 (sl) 2013-12-31
ZA200200823B (en) 2003-04-30
CZ2002386A3 (cs) 2002-07-17
CZ304624B6 (cs) 2014-08-13
BR0012863A (pt) 2002-04-16
WO2001008687A1 (en) 2001-02-08
AU4491200A (en) 2001-02-19
KR100738861B1 (ko) 2007-07-16
PL199137B1 (pl) 2008-08-29
EP1200091B1 (de) 2008-07-02
IL147641A0 (en) 2002-08-14
SK1732002A3 (en) 2002-05-09
CA2379948C (en) 2008-03-25
NO20020532D0 (no) 2002-02-01
HUP0202513A3 (en) 2004-06-28
US7182958B1 (en) 2007-02-27
MXPA02001196A (es) 2003-02-12
NZ516616A (en) 2003-07-25
EA004872B1 (ru) 2004-08-26
AU4490900A (en) 2001-02-19
DZ3179A1 (fr) 2001-02-08
ES2310166T3 (es) 2009-01-01
NO20020532L (no) 2002-03-26
KR20020014843A (ko) 2002-02-25
KR20060093355A (ko) 2006-08-24
IL147641A (en) 2007-12-03
US6841167B1 (en) 2005-01-11
CN1365282A (zh) 2002-08-21
CA2379948A1 (en) 2001-02-08
ES2435816T3 (es) 2013-12-23
DK1200090T3 (da) 2013-11-25
WO2001008686A1 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
DE60039357D1 (de) Pharmazeutische zusammensetzung enthaltend tadalafil
DK1242425T3 (da) N-(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)arylsulfonamid-forbindelser og deres anvendelse som herbicider
NO20031672D0 (no) Aza- og polyaza-naftalenylkarboksamider for anvendelse som HIV-integraseinhibitorer
NO20024099D0 (no) Lavdose entecavir-formulering og anvendelse
HUP0301083A3 (en) Synergistical herbicide composition and use thereof
MXPA03000753A (es) Derivados de benzimidazola, su preparacion y su aplicacion terapeutica.
IL161257A (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4(pde4) inhibitors
SI1272167T1 (sl) Dozirna formulacija, ki vsebuje ropinirol, s hidrofilnim/lipofilnim polimernimm matriksom
EE200200414A (et) Dihüdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis
ATE356625T1 (de) Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung enthaltend 5,8,14- triazatetracyclo (10.3.1.0(2,11) 0 (4,9) )- hexadeca-2(11) 3, 5,7, 9-pentaene
MXPA03004714A (es) Sales de una isotiazol-4-carboxamida y su uso como agentes de antihiperproliferacion.
AU2002335046A1 (en) The use of proton sequestering agents in drug formulations
AU2002227985A1 (en) Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
DK0988862T3 (da) Formulering indeholdende et antigen, en TH-1 inducerende adjuvant og en sparsomt vandoplöselig aminosyre til brug ved immunisering
ITRM20020042V0 (it) Manico componibile perfezionato, in particolare manico per scope e simili.
NO20014050D0 (no) 1-aryl-1,3,5-triazin-4-tion-2,6-dioner, fremstilling derav og anvendelse derav som herbicider
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
EP1719526A3 (de) Pharmazeutische Zubereitungen enthaltend einen P2T Rezeptor Antagonist und ein antithrombotisches Mittel
ITMI20001093A0 (it) Composizioni a rilascio controllato contenenti un principio attivo, preferibilmente melatonina, e processo di preparazione delle stesse.
AU2001235595A1 (en) 4-heteroaryl-1,4-diazabicyclo(3.2.2)nonane, preparation and therapeutic use thereof
MXPA03008896A (es) Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos.
PL371365A1 (en) Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors
SE0001916D0 (sv) Novel formulation
HUP0303682A3 (en) Herbicide composition, preparation and use thereof
HUP0402149A3 (en) Water-soluble phenylpyridazine derivatives, their use and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties